Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › hypereosinophilic syndrome

Hypereosinophilic syndrome

Subtypes of Hypereosinophilic syndrome

Eosinophilic pneumonia 1

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for hypereosinophilic syndrome

7 trials tracked for hypereosinophilic syndrome: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 44 citations.

7Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 2 Other / NA 1
  1. Phase 3 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Completed · 44 cited
  2. Phase 3 A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Completed · 44 cited
  3. Phase 4 Steroid Treatment for Hypereosinophilic Syndrome Completed · 12 cited
  4. Phase 3 Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) Completed
  5. Phase 2 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies Completed
  6. Phase 2 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed
Show 1 more trials
  1. N/A Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hypereosinophilic syndrome: what the trials found

Mepolizumab has demonstrated efficacy in managing hypereosinophilic syndrome (HES). In a Phase 3 trial, Mepolizumab was associated with significant improvements in clinical stability; specifically, the percentage of participants experiencing an HES flare or withdrawing from the study was significantly lower in the treatment group compared to the control group over a 32-week period (56% vs. 28%, p=0.002) and during the final weeks of the study (35% vs. 17%, p=0.020). Additionally, Mepolizumab was associated with a significantly longer time to first HES flare 4.

Mepolizumab also showed utility in reducing corticosteroid requirements. Data indicates that patients treated with Mepolizumab experienced reductions in mean daily oral corticosteroid (OCS) doses over 52 weeks, with several participants achieving an OCS dose of less than or equal to 7.5 mg during the final phase of treatment 1.

Glucocorticoid challenge was shown to result in a mean percent change in eosinophil count of -69.6% and -13.6% respectively 2.

Recent results — preliminary, needs further review

  • Nilotinib has been investigated for HES, but results are not yet corroborated 5.
  • Dasatinib (BMS-354825) has been investigated for HES, but results are not yet corroborated 6.
  • Imatinib Mesylate (Gleevec) has been investigated for HES, but results are not yet corroborated 7.

For the clinician treating this condition

  • Mepolizumab is associated with a significantly lower rate of HES flares and study withdrawals compared to control groups over 32 weeks 4.
  • Mepolizumab treatment may facilitate a reduction in the required daily dose of oral corticosteroids for patients with HES 1.
  • Glucocorticoid challenge can result in significant reductions in eosinophil counts 2.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review of anti-IL-5 biologics in hypereosinophilic syndrome kidney disease reports low certainty evidence
Allergy & Immunology Meta-analysis
Systematic review of anti-IL-5 biologics in hypereosinophilic syndrome kidney disease reports low certainty evidence New Clues Help Doctors Spot Kidney Trouble in Rare Blood Disease
This systematic review with narrative synthesis evaluates anti-IL-5 and IL-5Rα biologics in patients with histologically confirmed hypereosi…
A new review shows kidney issues in rare blood disorders are tricky to diagnose but may respond well to specific drugs.
Frontiers Apr 23, 2026
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis
Rheumatology Cohort
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis 15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Frontiers Apr 22, 2026
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases
Allergy & Immunology Sys. Review
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases New Asthma Drugs Target the Real Troublemakers Hiding in Your Lungs
This systematic review examined the use of anti-IL-5 and anti-IL-5Rα biologics in patients with severe eosinophilic asthma, chronic rhinosin…
New asthma drugs target the specific immune cells causing swelling and mucus in severe asthma, nasal polyps, and rare eosinophil diseases.
Frontiers Apr 16, 2026